| 高 麟,张 华,陈海丹,唐江利,吴仕燕.细菌溶解产物胶囊治疗支气管哮喘患儿的疗效及对血清CRP、SAA、PCT、FeNO水平的影响[J].现代生物医学进展英文版,2024,(13):2555-2559. |
| 细菌溶解产物胶囊治疗支气管哮喘患儿的疗效及对血清CRP、SAA、PCT、FeNO水平的影响 |
| The Therapeutic Effect of Bacterial Dissolution Product Capsules on Children with Bronchial Asthma and Their Impact on Levels of Serum CRP, SAA, PCT, and FeNO |
| Received:January 09, 2024 Revised:January 31, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.13.030 |
| 中文关键词: 支气管哮喘 细菌溶解产物胶囊 C反应蛋白 淀粉蛋白A 降钙素原 呼出气一氧化氮 |
| 英文关键词: Bronchial asthma Bacterial dissolution product capsules C-reactive protein Starch protein A Procalcitonin Exhaled nitric oxide |
| 基金项目:海南省卫生计生行业科研项目（16A200036） |
|
| Hits: 202 |
| Download times: 134 |
| 中文摘要: |
| 摘要 目的：探讨细菌溶解产物胶囊治疗支气管哮喘（BA）患儿的疗效及对血清C反应蛋白（CRP）、淀粉蛋白A（SAA）、降钙素原（PCT）、呼出气一氧化氮（FeNO）水平的影响。方法：研究对象选自2021年12月~2023年7月我院诊治的BA患儿，共纳入80例，分为A组和B组各40例，分组方法为随机数字表法。两组均给予常规对症治疗，采用吸入用布地奈德混悬液对A组患者进行治疗，A组患者治疗的基础上，采用细菌溶解产物胶囊对B组患者进行治疗。两组均持续治疗3个月。比较两组治疗3个月后的临床疗效，恢复进度及治疗期间下呼吸道感染、上呼吸道感染、哮喘发作次数，治疗前、治疗3个月后的肺功能、血清CRP、SAA、PCT、FeNO水平，治疗期间的安全性。结果：治疗3个月后，B组总有效率为95.00%，高于A组的77.50%（P<0.05）。相比于A组，B组咳嗽缓解时间以及消失时间均更短；治疗期间，B组下呼吸道感染、上呼吸道感染、哮喘发作次数均低于A组（P<0.05）。与治疗前比较，治疗3个月后，两组肺功能指标均升高，且相比于A组，B组更高（P<0.05）。与治疗前比较，治疗3个月后，两组血清CRP、SAA、PCT、FeNO水平均降低，且相比于A组，B组更低（P<0.05）。治疗期间，B组和A组的不良反应发生率比较无差异（22.50% vs 17.50%，P>0.05）。结论：细菌溶解产物胶囊可显著促进BA患儿哮喘及呼吸道感染症状的缓解，提高患儿肺功能，并减轻患儿炎症反应，进而提高治疗效果，且安全性良好。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the therapeutic effect of bacterial dissolution product capsules on children with bronchial asthma (BA) and their impact on levels of serum C-reactive protein (CRP), amyloid A (SAA), procalcitonin (PCT), and exhaled nitric oxide (FeNO). Methods: The research subjects were selected from children with BA who were treated in our hospital from December 2021 to July 2023. A total of 80 cases were included and divided into the group A and the group B, with 40 cases in each group. The grouping method was random number table method. Both groups were given routine symptomatic treatment, using inhaled budesonide suspension to treat the group A patients. On the basis of treatment for the group A patients, bacterial dissolution product capsules were used to treat the group B patients. The clinical efficacy, recovery progress, lower respiratory tract infection, upper respiratory tract infection, frequency of asthma attacks during treatment, lung function, levels of serum CRP, SAA, PCT, FeNO before and after 3 months of treatment, and evaluate the safety during treatment between two groups were compared. Results: After 3 months of treatment, the rate of total effective in the group B was 95.00%, which was higher than 77.50% of the group A(P<0.05). Compared with the the group A, the relief and disappearance time of cough in the group B were shorter; During treatment, The frequency of lower respiratory tract infections, upper respiratory tract infections, and asthma attacks in the group B were all lower than those in the group A(P<0.05). Compared with before treatment, after 3 months of treatment, the lung function indicators of both groups increased, and compared with the the group A, the group B was higher(P<0.05). Compared with before treatment, after 3 months of treatment, the levels of serum CRP, SAA, PCT, and FeNO in both groups decreased, and compared with the the group A, the group B was lower(P<0.05). During the treatment period, there was no significant difference in the incidence of adverse reactions between the group B and the group A (22.50% vs 17.50%, P>0.05). Conclusion: Bacterial dissolution product capsules could significantly promote the relief of asthma and respiratory infection symptoms in children with BA, improve lung function, alleviate inflammatory reactions in children, and thus improve treatment effectiveness with good safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
